Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival.
adenocarcinoma
cervical cancer
locally advanced
neoadjuvant chemotherapy
radical hysterectomy
squamous
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
30 Jan 2019
30 Jan 2019
Historique:
received:
25
12
2018
revised:
24
01
2019
accepted:
27
01
2019
entrez:
2
2
2019
pubmed:
2
2
2019
medline:
2
2
2019
Statut:
epublish
Résumé
The current study examined the histology-specific impact of neoadjuvant chemotherapy (NACT) with a taxane/platinum regimen on survival in women with locally-advanced cervical cancer who underwent radical hysterectomy. This nation-wide retrospective cohort study examined women with clinical stage IB2-IIB cervical cancer who received NACT prior to radical hysterectomy from 2004⁻2008 (
Identifiants
pubmed: 30704058
pii: jcm8020156
doi: 10.3390/jcm8020156
pmc: PMC6406495
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2001 Mar 1;19(5):1275-8
pubmed: 11230468
J Clin Oncol. 2002 Jan 1;20(1):179-88
pubmed: 11773168
Eur J Gynaecol Oncol. 2003;24(1):51-9
pubmed: 12691318
Ann Oncol. 2003 Aug;14(8):1278-84
pubmed: 12881393
J Clin Oncol. 2004 Aug 1;22(15):3113-9
pubmed: 15284262
Gynecol Oncol. 2005 Mar;96(3):805-9
pubmed: 15721429
J Clin Oncol. 2005 Jun 20;23(18):4137-45
pubmed: 15961761
Gynecol Oncol. 2005 Nov;99(2):376-82
pubmed: 16051322
J Obstet Gynaecol Res. 2006 Jun;32(3):315-23
pubmed: 16764623
Gynecol Oncol. 2007 Aug;106(2):362-9
pubmed: 17493669
Gynecol Oncol. 2008 Sep;110(3):308-15
pubmed: 18606439
Arch Gynecol Obstet. 2010 Feb;281(2):325-8
pubmed: 19455347
J Clin Oncol. 2009 Oct 1;27(28):4649-55
pubmed: 19720909
Gynecol Oncol. 2010 Jan;116(1):140-6
pubmed: 19880165
Int J Gynecol Cancer. 2010 May;20(4):611-6
pubmed: 20686381
Gynecol Oncol. 2011 Nov;123(2):241-7
pubmed: 21820708
J Med Assoc Thai. 2012 Mar;95 Suppl 3:S55-61
pubmed: 22619888
Eur J Surg Oncol. 2013 Feb;39(2):115-24
pubmed: 23084091
Cochrane Database Syst Rev. 2012 Dec 12;12:CD007406
pubmed: 23235641
Gynecol Oncol. 2013 Apr;129(1):124-8
pubmed: 23353129
Tumour Biol. 2014 Mar;35(3):2741-6
pubmed: 24234333
N Engl J Med. 2014 Feb 20;370(8):734-43
pubmed: 24552320
Int J Gynaecol Obstet. 2014 May;125(2):97-8
pubmed: 24630859
Int J Gynecol Cancer. 2014 Sep;24(7):1333-40
pubmed: 25078340
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
J Clin Oncol. 2015 Jul 1;33(19):2129-35
pubmed: 25732161
Int J Clin Oncol. 2015 Apr;20(2):240-8
pubmed: 25800808
Ann Surg Oncol. 2016 Jan;23(1):163-70
pubmed: 25916979
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S971-8
pubmed: 26014155
Int J Clin Exp Med. 2015 Aug 15;8(8):13690-8
pubmed: 26550314
J Obstet Gynaecol Res. 2016 Sep;42(9):1069-79
pubmed: 27338217
Int J Clin Oncol. 2016 Dec;21(6):1128-1135
pubmed: 27380169
Cochrane Database Syst Rev. 2016 Nov 22;11:CD005342
pubmed: 27873308
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
Anticancer Res. 2017 Mar;37(3):1249-1255
pubmed: 28314289
Int J Cancer. 2017 Sep 1;141(5):1042-1051
pubmed: 28524247
J Gynecol Oncol. 2017 Jul;28(4):e60
pubmed: 28541644
Int J Gynecol Cancer. 2017 Jul;27(6):1256-1260
pubmed: 28574931
Int J Cancer. 2018 Mar 1;142(5):1022-1032
pubmed: 28975603
J Gynecol Oncol. 2018 Jan;29(1):e11
pubmed: 29185269
Oncotarget. 2017 Nov 15;8(63):106866-106875
pubmed: 29290995
J Clin Oncol. 2018 Jun 1;36(16):1548-1555
pubmed: 29432076
J Gynecol Oncol. 2018 Nov;29(6):e91
pubmed: 30207099
J Clin Oncol. 1994 Nov;12(11):2309-16
pubmed: 7964945
Lancet. 1997 Aug 23;350(9077):535-40
pubmed: 9284774
Gynecol Oncol. 1997 Oct;67(1):61-9
pubmed: 9345358
Anticancer Res. 1998 Nov-Dec;18(6B):4575-9
pubmed: 9891521